EDMONTON, Alberta--(BUSINESS WIRE)--Dec. 8, 2005--ViRexx Medical Corp. (TSX:VIR) a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, announced today that it has filed a Clinical Trial Application with Health Canada for a Phase I trial of HepaVaxx B, an important proof of principle for the Chimigen(TM) platform. HepaVaxx B is being developed as a therapeutic vaccine for the treatment of patients chronically infected with hepatitis B.
